Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

worldpharmanewsMarch 27, 2019

Tag: FDA , EMA , Boehringer Ingelheim , sclerosis , nintedanib

PharmaSources Customer Service